Request demo
Picture of Martin Slater

Martin Slater

Martin studied medicinal chemistry at the Universities of Huddersfield and Leeds, and spent 14 years in the highly dynamic pharmaceutical ‘fee for service’ environment at BioFocus in which he supported medicinal chemistry and a diverse range of programs.

Science Resources

The power of combining computational chemistry with experimental drug repurposing
Request Webinar Link+ First broadcast with C&EN 22nd March 2023 Computational chemistry offers a fast and innovative approach to drug discovery...
Identify novel compounds and increase the diversity of your ligand modifications using fragment-based drug discovery
Introduction Fragment-based drug discovery (FBDD) is well-established as an effective method for advancing innovative drug design and has...
New modalities for 3D virtual screening of ultra-large chemical spaces
What does scaffold hopping mean to you?
We explore the different meanings of scaffold hopping in drug discovery
Accelerating discovery of a METTL3 inhibitor through efficient in silico design and prioritization
Cresset Discovery provides molecular modeling expertise utilizing the application of proprietary in silico methods which, when combined with...
Discovery and development of EP652, A METTL3 Inhibitor with efficacy in liquid and Solid Tumour Models
We highlight computational analysis and modeling that facilitated in-silico design; providing a potent, active and tractable METTL3 inhibitor...

News Articles

Resurrection of the covalent inhibitor?
There has been a revival of interest in covalent inhibitors in recent years. This has culminated in a growing list of diverse proteins that have...
Modeling ‘big’: Applying the XED force field to biologics
Cresset is well known for powerful and accurate ligand-centric modeling, and Flare has established our methods for protein-ligand interactions....
Modeling the intricacies of molecular recognition: Make ‘smart antibodies’ into biologics
Antibodies are fantastically versatile molecular recognition engines, capable of creating artificial enzymes in response to recognized interactions....
Therapeutic protein degradation by design?
The old problem and the new paradigm Classical small molecule drug paradigms generally involve intervention at a ligand protein binding site....
The importance of understanding protein-protein and protein-ligand interactions in immuno-oncology
Historical context and significance Despite cancer being a disease that has been with us for centuries, it has never been as important as it is now...
Highlights from the 20th Joint SCI/RSC Medicinal Chemistry Symposium, Cambridge, UK
In my humble opinion, this meeting is one of the best medicinal chemistry conferences to attend and as usual the scientific content, on the whole,...
Review of the 6th RSC/SCI Ion Channels as Therapeutic Targets Symposium
Introduction This bi-annual event was, as usual, of a high scientific standard with a great line-up of talks. One main difference between this...
The case for outsourcing computational chemistry in drug discovery
Dr Martin Slater, Director of Consulting Services, explains why outsourcing computational chemistry could be the key to maximizing ROI in pharmaceutical...
Streamlining molecular discovery
Following on from his blog on ‘The case for outsourcing computational chemistry in drug discovery‘, Dr Martin Slater, Director...
Discovering a novel therapy for urinary tract infections through outsourcing in-silico drug discovery
We were delighted to welcome Dr Ashraf Zarkan from the Department of Genetics, University of Cambridge to deliver a webinar on ‘Discovering...
Combined In Silico and In Vitro Evidence Supporting an Aurora A Kinase Inhibitory Role of the Anti-Viral Drug Rilpivirine and an Anti-Proliferative Influence on Cancer Cells
Computational chemistry offers a fast and innovative approach to drug discovery and is especially powerful when used in combination with biological...
Cresset Discovery accelerates optimization of METTL3 inhibitor
Cresset Discovery has delivered a highly efficient digital workflow combining their molecular modeling expertise with Cresset technology...

Blog

Resurrection of the covalent inhibitor?
There has been a revival of interest in covalent inhibitors in recent years. This has culminated in a growing list of diverse proteins that have...
Modeling ‘big’: Applying the XED force field to biologics
Cresset is well known for powerful and accurate ligand-centric modeling, and Flare has established our methods for protein-ligand interactions....
Modeling the intricacies of molecular recognition: Make ‘smart antibodies’ into biologics
Antibodies are fantastically versatile molecular recognition engines, capable of creating artificial enzymes in response to recognized interactions....
Therapeutic protein degradation by design?
The old problem and the new paradigm Classical small molecule drug paradigms generally involve intervention at a ligand protein binding site....
The importance of understanding protein-protein and protein-ligand interactions in immuno-oncology
Historical context and significance Despite cancer being a disease that has been with us for centuries, it has never been as important as it is now...
Highlights from the 20th Joint SCI/RSC Medicinal Chemistry Symposium, Cambridge, UK
In my humble opinion, this meeting is one of the best medicinal chemistry conferences to attend and as usual the scientific content, on the whole,...
Review of the 6th RSC/SCI Ion Channels as Therapeutic Targets Symposium
Introduction This bi-annual event was, as usual, of a high scientific standard with a great line-up of talks. One main difference between this...
The case for outsourcing computational chemistry in drug discovery
Dr Martin Slater, Director of Consulting Services, explains why outsourcing computational chemistry could be the key to maximizing ROI in pharmaceutical...
Streamlining molecular discovery
Following on from his blog on ‘The case for outsourcing computational chemistry in drug discovery‘, Dr Martin Slater, Director...
Discovering a novel therapy for urinary tract infections through outsourcing in-silico drug discovery
We were delighted to welcome Dr Ashraf Zarkan from the Department of Genetics, University of Cambridge to deliver a webinar on ‘Discovering...
Combined In Silico and In Vitro Evidence Supporting an Aurora A Kinase Inhibitory Role of the Anti-Viral Drug Rilpivirine and an Anti-Proliferative Influence on Cancer Cells
Computational chemistry offers a fast and innovative approach to drug discovery and is especially powerful when used in combination with biological...
Cresset Discovery accelerates optimization of METTL3 inhibitor
Cresset Discovery has delivered a highly efficient digital workflow combining their molecular modeling expertise with Cresset technology...